BLFS
Price
$22.58
Change
+$0.32 (+1.44%)
Updated
Jul 25 closing price
Capitalization
810.87M
12 days until earnings call
CDNA
Price
$12.79
Change
-$0.05 (-0.39%)
Updated
Jul 25 closing price
Capitalization
548.33M
11 days until earnings call
Interact to see
Advertisement

BLFS vs CDNA

Header iconBLFS vs CDNA Comparison
Open Charts BLFS vs CDNABanner chart's image
BioLife Solutions
Price$22.58
Change+$0.32 (+1.44%)
Volume$325.39K
Capitalization810.87M
CareDx
Price$12.79
Change-$0.05 (-0.39%)
Volume$877.59K
Capitalization548.33M
BLFS vs CDNA Comparison Chart in %
Loading...
BLFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BLFS vs. CDNA commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a Hold and CDNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (BLFS: $22.58 vs. CDNA: $12.79)
Brand notoriety: BLFS and CDNA are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BLFS: 60% vs. CDNA: 58%
Market capitalization -- BLFS: $810.87M vs. CDNA: $548.33M
BLFS [@Medical Specialties] is valued at $810.87M. CDNA’s [@Medical Specialties] market capitalization is $548.33M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BLFS’s FA Score shows that 1 FA rating(s) are green whileCDNA’s FA Score has 0 green FA rating(s).

  • BLFS’s FA Score: 1 green, 4 red.
  • CDNA’s FA Score: 0 green, 5 red.
According to our system of comparison, BLFS is a better buy in the long-term than CDNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLFS’s TA Score shows that 4 TA indicator(s) are bullish while CDNA’s TA Score has 5 bullish TA indicator(s).

  • BLFS’s TA Score: 4 bullish, 3 bearish.
  • CDNA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BLFS is a better buy in the short-term than CDNA.

Price Growth

BLFS (@Medical Specialties) experienced а +8.40% price change this week, while CDNA (@Medical Specialties) price change was +7.34% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.05%. For the same industry, the average monthly price growth was +5.16%, and the average quarterly price growth was -1.87%.

Reported Earning Dates

BLFS is expected to report earnings on Aug 07, 2025.

CDNA is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Medical Specialties (+3.05% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BLFS($811M) has a higher market cap than CDNA($548M). BLFS YTD gains are higher at: -13.020 vs. CDNA (-40.262). BLFS has higher annual earnings (EBITDA): -45.24M vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. BLFS (51.7M). CDNA has less debt than BLFS: CDNA (34.2M) vs BLFS (42.7M). CDNA has higher revenues than BLFS: CDNA (280M) vs BLFS (143M).
BLFSCDNABLFS / CDNA
Capitalization811M548M148%
EBITDA-45.24M-84.92M53%
Gain YTD-13.020-40.26232%
P/E Ratio238.10N/A-
Revenue143M280M51%
Total Cash51.7M235M22%
Total Debt42.7M34.2M125%
FUNDAMENTALS RATINGS
BLFS vs CDNA: Fundamental Ratings
BLFS
CDNA
OUTLOOK RATING
1..100
196
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
9046
PRICE GROWTH RATING
1..100
6294
P/E GROWTH RATING
1..100
1594
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BLFS's Valuation (95) in the Medical Specialties industry is in the same range as CDNA (96). This means that BLFS’s stock grew similarly to CDNA’s over the last 12 months.

BLFS's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as CDNA (100). This means that BLFS’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's SMR Rating (46) in the Medical Specialties industry is somewhat better than the same rating for BLFS (90). This means that CDNA’s stock grew somewhat faster than BLFS’s over the last 12 months.

BLFS's Price Growth Rating (62) in the Medical Specialties industry is in the same range as CDNA (94). This means that BLFS’s stock grew similarly to CDNA’s over the last 12 months.

BLFS's P/E Growth Rating (15) in the Medical Specialties industry is significantly better than the same rating for CDNA (94). This means that BLFS’s stock grew significantly faster than CDNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BLFSCDNA
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
BLFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UIVRX12.990.08
+0.62%
MFS Intrinsic Value R6
FMIHX15.750.05
+0.32%
FMI Large Cap Investor
NMAVX12.430.04
+0.32%
Nuance Mid Cap Value Investor
FEUIX29.63N/A
N/A
Fidelity Advisor Glbl Capital Apprec I
VTCAX88.08-0.52
-0.59%
Vanguard Communication Svcs Idx Admiral

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with NTRA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-0.39%
NTRA - CDNA
42%
Loosely correlated
-1.53%
VCYT - CDNA
41%
Loosely correlated
+7.04%
BLFS - CDNA
39%
Loosely correlated
+1.44%
LMAT - CDNA
35%
Loosely correlated
+2.06%
ABT - CDNA
35%
Loosely correlated
+0.72%
More